Pancreatic cancer suitable for treatment with Active Biotech's TTS cancer products
The final report of Phase IIa study on patients with pancreas cancer at a progressive stage treated with TTS (Tumour Targeted Superantigens) candidate drug CD2 shows encouraging results.
The primary endpoint was defined as the number of responders to treatment. 19 patients started TTS CD2 treatment and after 2 months 5 (26%) of the patients showed stable disease (SD). Four of the patients still showed SD 4 months after start of TTS treatment. Median survival time was 148 days.
Of the total number of pancreatic cancer patients included in the study, all 19 had previously received other treatment for pancreatic cancer, 18 (95%) had received prior chemotherapy and 17 (89%) had received chemotherapy with gemcitabine. The relatively high frequency of patients with stable disease (SD) in the study indicates a biological activity of the TTS compound. Furthermore, the TTS products possess a unique, immune-mediated mode of action with few and mild side effects.
"Pancreatic cancer is one of the most difficult cancers to treat. Since the patients included in this trial had advanced disease and had almost all been pre-treated with gemcitabine, a median survival time of 148 days is encouraging - the median survival of patients treated with first line therapy on the pivotal trial with gemcitabine was 170 days", says Professor Robert Hawkins, Principal Investigator, Christie Hospital in Manchester, UK.
"Our study also shows that TTS is well tolerated by the patients and treatment of this very severe type of cancer is feasible", concludes Professor Hawkins.
Other news from the department business & finance
